Sant P. Chawla

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2K citations · Full text

Metastatic Soft-tissue Sarcoma, Placebo-controlled Phase 3, Medicine +8

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 770 citations

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 753 citations · Full text

Oncology, Metronomic Therapy, Pharmacology +6

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

David M. Thomas, Robert M. Henshaw, Keith M. Skubitz et al. · The Lancet Oncology · 2010 · 703 citations

Bone Disease, Malignant Disease, Medicine +7